Thyroid Hormone Analogue Shows Promise for Treating High Cholesterol
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Thyroid Hormone Analogue Shows Promise for Treating High Cholesterol

MANHASSET, NY -- March 12, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published in this week’s edition of the New England Journal of Medicine.

An international team of investigators from Johns Hopkins Medical Institutions, Baltimore, Maryland, the Karolinska University Hospital and Institute, Stockholm, Sweden, and the Feinstein Institute for Medical Research, Manhasset, New York, tested a substance called eprotirome in patients with high cholesterol.

Following 189 people with high cholesterol over a 3-month period, they observed that it lowered cholesterol levels without the classic thyroid risks to the heart and bone.

In the current phase 2 study, 189 patients already taking simvastatin or atorvastatin were randomised to also receive either placebo or 1 of 3 doses of eprotirome daily.

After 12 weeks, data indicated that patients who received eprotirome had placebo-adjusted reductions in serum low-density lipoprotein (LDL) cholesterol concentrations that were between 15% for the lowest dose and 26% for the highest dose.

The results also showed similar reductions in apolipoprotein B, as well as reductions in other risk factors for cardiovascular disease, such as triglycerides and lipoprotein A.

What is not known from this study is whether this lowering of cholesterol will ultimately protect patients from heart disease.

“Every percentage that you lower cholesterol, you lower the risk for heart disease,” said Irwin Klein, MD, Feinstein Institute. “High cholesterol is the single most modifiable risk factor.”

The next phase of testing must include larger numbers of patients. If the results hold, it could ultimately be used as an alternative to statins. A small percentage of patients can’t take statins, either because they don’t work to lower cholesterol for them or they suffer from unrelenting side effects such as muscle pains, myopathy, and tiredness.

SOURCE: North Shore-Long Island Jewish Health System

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities